- Home
- NBTX vs ACIU Comparison
NBTX vs ACIU Comparison
Compare NBTX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- ACIU
- Stock Information
- Founded
- NBTX 2003
- ACIU 2003
- Country
- NBTX France
- ACIU Switzerland
- Employees
- NBTX N/A
- ACIU N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- ACIU Health Care
- Exchange
- NBTX Nasdaq
- ACIU Nasdaq
- Market Cap
- NBTX 178.7M
- ACIU 173.7M
- IPO Year
- NBTX 2020
- ACIU 2016
- Fundamental
- Price
- NBTX $3.41
- ACIU $1.68
- Analyst Decision
- NBTX Strong Buy
- ACIU Strong Buy
- Analyst Count
- NBTX 1
- ACIU 2
- Target Price
- NBTX $8.00
- ACIU $10.00
- AVG Volume (30 Days)
- NBTX 7.6K
- ACIU 133.4K
- Earning Date
- NBTX 04-02-2025
- ACIU 04-30-2025
- Dividend Yield
- NBTX N/A
- ACIU N/A
- EPS Growth
- NBTX N/A
- ACIU N/A
- EPS
- NBTX N/A
- ACIU N/A
- Revenue
- NBTX N/A
- ACIU $32,014,254.00
- Revenue This Year
- NBTX N/A
- ACIU N/A
- Revenue Next Year
- NBTX $221.06
- ACIU $676.94
- P/E Ratio
- NBTX N/A
- ACIU N/A
- Revenue Growth
- NBTX N/A
- ACIU 91.20
- 52 Week Low
- NBTX $2.76
- ACIU $1.43
- 52 Week High
- NBTX $7.51
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- NBTX 52.75
- ACIU 46.75
- Support Level
- NBTX $3.26
- ACIU $1.55
- Resistance Level
- NBTX $3.65
- ACIU $1.79
- Average True Range (ATR)
- NBTX 0.19
- ACIU 0.10
- MACD
- NBTX 0.02
- ACIU 0.03
- Stochastic Oscillator
- NBTX 35.00
- ACIU 66.67
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.